UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

Bellerophon Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.01 par value per share (Title of Class of Securities)

078771300 (CUSIP Number)

December 31, 2023 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 078771300

1	NAMES OF REPORTING PERSONS						
		Perceptive Advisors LLC					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) (c)						
3	SEC USE C	NL	Y				
4	CITIZENSI	HIP	OR PLACE OF ORGANIZATION				
	Delaware	laware					
		5	SOLE VOTING POWER				
NUMBER OF			0				
SHARES BENEFICIALLY		6	SHARED VOTING POWER				
	WNED BY		0				
RI	EACH EPORTING	7	SOLE DISPOSITIVE POWER				
	PERSON WITH:						
	W1111.	8	SHARED DISPOSITIVE POWER				
		TE	0				
9	AGGREGA	ILE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
10	0 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9						
11							
12	0.0% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
12							
	IA						

CUSIP No. 078771300

1	NAMES O	F RE	EPORTING PERSONS			
	Joseph Edelman					
2	,					
	(a) □	(D) I				
3	SEC USE C	ONL	Y			
4	CITIZENSHIP OR PLACE OF ORGANIZATION					
	CITELINGIAL OKTERCE OF ORGANIZATION					
	United States of America					
		5	SOLE VOTING POWER			
NUMBER OF			0			
SHARES		6	SHARED VOTING POWER			
	BENEFICIALLY					
O	WNED BY EACH	7	0 SOLE DISPOSITIVE POWER			
RI	EPORTING	/	SOLE DISPOSITIVE POWER			
	PERSON					
	WITH:	8	SHARED DISPOSITIVE POWER			
9	ACCDEGA	TE	0 AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
,	AUUKEUA	II L	AMOUNT BENEFICIALLY OWNED BY EACH REFORTING FERSON			
	0					
10	CHECK BO	OX I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
	П					
11						
	TERCENT OF CENES ARTHUS BITHING IN INC.					
	0.0%					
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
	IN					
	221					

CUSIP No. 078771300

1	NAMES OF REPORTING PERSONS					
	Perceptive Life Sciences Master Fund, Ltd.					
2			APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)			
	(a) 🗆	(b)				
3	SEC USE O	ONL	Y			
	araran ra					
4	CITIZENSHIP OR PLACE OF ORGANIZATION					
	Cayman Islands					
	•	5	SOLE VOTING POWER			
NAME OF OF						
NUMBER OF SHARES		6	SHARED VOTING POWER			
	NEFICIALLY					
O	WNED BY EACH	7	0 SOLE DISPOSITIVE POWER			
REPORTING		,	SOLL DISTOSITIVE TOWER			
	PERSON WITH:					
WIIH:		8	SHARED DISPOSITIVE POWER			
			0			
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	0					
10		OX I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9					
12	0.0% TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)					
14	TILLOFF	XLI'V	okting i Ekson (SEE instructions)			
	CO					

Item 1(a). Name of Issuer:

Bellerophon Therapeutics, Inc. (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

c/o Verdolino & Lowey, P.C. 124 Washington Street, Suite 101, Foxborough, MA 02035

Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the "Reporting Persons") are:

Perceptive Advisors LLC ("Perceptive Advisors")
Joseph Edelman ("Mr. Edelman")
Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Reporting Persons is:

51 Astor Place, 10th Floor New York, NY 10003

Item 2(c). <u>Citizenship</u>:

Perceptive Advisors is a Delaware limited liability company Mr. Edelman is a United States citizen The Master Fund is a Cayman Islands corporation

Item 2(d). <u>Title of Class of Securities</u>:

Common Stock, \$0.01 par value per share ("Common Stock")

Item 2(e). CUSIP Number:

078771300

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 12,232,648 shares of Common Stock outstanding as reported by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on December 12, 2023.

The Master Fund directly holds 0 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own shares held by the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own shares held by the Master Fund.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \boxtimes .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: February 14, 2024

PERCEPTIVE ADVISORS LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member

/s/ Joseph Edelman

JOSEPH EDELMAN

PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

By: Perceptive Advisors LLC

By: /s/ Joseph Edelman

Name: Joseph Edelman Title: Managing Member